Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …

In women at risk of early preterm imminent birth, from viability to 30 weeks of gestation, use
of MgSO4 for neuroprotection of the fetus is recommended. In pregnancies below 32–34 …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

The neuro-protective effect of antenatal magnesium sulfate on very preterm infants has been
demonstrated in good-quality randomised controlled trials and meta-analyses. Magnesium …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

Background Intrapartum magnesium sulfate administration is recommended for fetal
neuroprotection in women with imminent very preterm birth. However, previous studies have …